The combination of the two drugs increased the rate of immune response in lung cancer patients by more than fivefold. This has been shown by a study published in the journal. Nature Medicine.
Cancer immunotherapy—stimulating the human immune system to destroy cancer cells—has become a breakthrough in oncology. However, its effectiveness depends on the patient’s immune response. In a new study, scientists found a drug combination that increases the likelihood of an immune response in lung cancer.
The trial included 268 patients with advanced stages of non-small cell lung cancer who did not benefit from standard treatment. The average age of the participants was 64 years and 58% were male.
They took the drug durvalumab and one of four drugs: ceralasertib, olaparib, oleclumab, or danvatirsen.
The combination of durvalumab + ceralasertib caused an immune response in 13.9% of patients, compared to 2.6% with other combinations. Median progression-free survival was approximately 6 months versus 2.7 months for the other combinations, and overall survival was 17.4 months versus 9.4 months.
used to be a doctor explainedDoes tumor marker testing help detect cancer?